Ann: Response to ASX Appendix 4C Query, page-7

Points 10 - 13 as follows;

10. The Company continues to be in negotiations with an external party to divest the non-core Infusion business. While negotiations between the parties have advanced, no binding offer has been received, and negotiations are incomplete (the Infusion Transaction). 11. If the Company cannot complete the divestiture of the Infusion business within the short term, then it remains confident that it can complete another capital transaction. As a result of capital raisings undertaken in 2018, the Company has two substantial shareholders that the Company would intend to engage with for any planned capital transaction. 12. The Company is also considering its options with respect to the TAVR project, including the potential for a strategic partnership with a medical device company and has commenced early stage discussions with potential partners in relation to this. 13. If the Company makes the decision to raise further capital, it will provide details of that activity as and when required by the ASX Listing Rules.


I was thinking the same Burnett, regarding a buyer the Infusion business.
Get the impression they might be keeping things close to their chest. 
It would be interesting to see how far the TAVR discussions have advanced.

Regards
Dabru